436
Views
14
CrossRef citations to date
0
Altmetric
Cosmetic dermatology and surgery

Combined treatment of hidradenitis suppurativa with intense pulsed light (IPL) and radiofrequency (RF)

ORCID Icon, , ORCID Icon, ORCID Icon, , ORCID Icon & ORCID Icon show all
Pages 530-537 | Received 10 Aug 2019, Accepted 21 Sep 2019, Published online: 17 Oct 2019

References

  • Gill L, Williams M, Hamzavi I. Update on hidradenitis suppurativa: connecting the tracts. F1000Prime Rep. 2014;6:112.
  • Jemec GB. Clinical practice. Hidradenitis suppurativa. N Engl J Med. 2012;366(2):158–164.
  • Wolkenstein P, Loundou A, Barrau K, et al. Quality of life group of the French society of dermatology. Quality of life impairment in hidradenitis suppurativa: a study of 61 cases. J Am Acad Dermatol. 2007;56(4):621–623.
  • Zouboulis CC, Desai N, Emtestam L, et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol. 2015;29(4):619–644.
  • Falola RA, DeFazio MV, Anghel EL, et al. What heals hidradenitis suppurativa: surgery, immunosuppression, or both? Plast Reconstr Surg. 2016;138:219S–229S.
  • Mendonca CO, Griffiths CE. Clindamycin and rifampicin combination therapy for hidradenitis suppurativa. Br J Dermatol. 2006;154(5):977–978.
  • Jemec GB, Wendelboe P. Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa. J Am Acad Dermatol. 1998;39(6):971–974.
  • Hazen PG, Hazen BP. Hidradenitis suppurativa: successful treatment using carbon dioxide laser excision and marsupialization. Dermatol Surg. 2010;36(2):208–213.
  • Mehdizadeh A, Hazen PG, Bechara FG, et al. Recurrence of hidradenitis suppurativa after surgical management: a systematic review and meta-analysis. J Am Acad Dermatol. 2015;73:70–77.
  • Kaminaka C, Uede M, Matsunaka H, et al. Clinical studies of the treatment of facial atrophic acne scars and acne with a bipolar fractional radiofrequency system. J Dermatol. 2015;42(6):580–587.
  • Piccolo D, Di Marcantonio D, Crisman G, et al. Unconventional use of intense pulsed light. Biomed Res Int. 2014;2014:1.
  • Highton L, Chan WY, Khwaja N, et al. Treatment of hidradenitis suppurativa with intense pulsed light: a prospective study. Plast Reconstr Surg. 2011;128(2):459–465.
  • Saunte DM, Lapins J. Lasers and intense pulsed light hidradenitis suppurativa. Dermatol Clin. 2016;34(1):111–119.
  • Hamzavi IH, Griffith JL, Riyaz F, et al. Laser and light-based treatment options for hidradenitis suppurativa. J Am Acad Dermatol. 2015;73(5):S78–S81.
  • Ruiz-Esparza J, Gomez JB. Nonablative radiofrequency for active acne vulgaris: the use of deep dermal heat in the treatment of moderate to severe active acne vulgaris (thermotherapy): a report of 22 patients. Dermatol Surg. 2003;29:333–339.
  • Iwasaki J, Marra DE, Fincher EF, Moy RL. Treatment of hidradenitis suppurativa with a nonablative radiofrequency device. Dermatol Sur. 2008;34(1):114–117.
  • Finlay AY, Khan GK. Dermatology life quality index (DLQI)–a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210–216.
  • El-Latif AA, Hassan FA, Elshahed AR, et al. Intense pulsed light versus benzoyl peroxide 5% gel in treatment of acne vulgaris. Lasers Med Sci. 2014;29(3):1009–1015.
  • Kawana S, Tachihara R, Kato T, et al. Effect of smooth pulsed light at 400 to 700 and 870 to 1,200 nm for acne vulgaris in Asian skin. Dermatol Surg. 2010;36(1):52–57.
  • Yeung CK, Shek SY, Bjerring P, et al. A comparative study of intense pulsed light alone and its combination with photodynamic therapy for the treatment of facial acne in Asian skin. Lasers Surg Med. 2007;39(1):1–6.
  • Ali MM, Porter RM, Gonzalez ML. Intense pulsed light enhances transforming growth factor beta1/Smad3 signaling in acne-prone skin. J Cosmet Dermatol. 2013;12(3):195–203.
  • Yu JN, Huang P. Use of a TriPollar radio-frequency device for the treatment of acne vulgaris. J Cosmet Laser Ther. 2011;13(2):50–53.
  • Kimball AB, Okun MM, Williams DA, et al. Two phase 3 trials of adalimumab for hidradenitis suppurativa. N Engl J Med. 2016;375(5):422–434.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.